The U.S. Food and Drug Administration is alerting pet owners and veterinarians to be aware of the potential for neurologic reactions in dogs and cats when treated with some flea and tick products.
The FDA found during routine inspection that some animals receiving the drugs Bravecto, Nexgard or Simparica have experienced reactions such as muscle tremors, ataxia, and seizures.
The drugs are all part of the isoxazoline class.
Another product in this class, Credelio, recently received FDA approval. These products are approved for the treatment and prevention of flea infestations, and the treatment and control of tick infestations.
“The FDA is working with manufacturers of isoxazoline products to include new label information to highlight neurologic events because these events were seen consistently across the isoxazoline class of products,” according to a press release.
The FDA said these products continue to be safe and effective for the majority of animals. “Veterinarians should use their specialized training to review their patients’ medical histories and determine, in consultation with pet owners, whether a product in the isoxazoline class is appropriate for the pet,” according to the FDA.
To report suspected adverse drug events for these products and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, contact the appropriate manufacturers at the following phone numbers:
Merck Animal Health (Bravecto): 800-224-5318
Elanco Animal Health (Credelio): 888-545-5973
Merial (Nexgard): 888-637-4251
Zoetis (Simparica): 888-963-8471